The available record for Xiaoqin Xiang is a single 2024 Chemical Science publication describing a chemoselective orthophthalaldehyde (OPA) cyclization strategy on M13 phage display, producing a 109-member cyclic peptide library (KX7C) that yielded micromolar binders to human PTP1B, NEK7, and hKeap1 . This is a methodologically demanding, interdisciplinary contribution β the strongest signal of scientific competence in the record.
The affinity comparison shows consistent single-digit micromolar binding for cyclic (OPA) hits versus weak or absent binding of linear (disulfide/SS) precursors β a strong internal control demonstrating that cyclization, not selection artifact, drives binding .
Strengths: multi-technique validation (ESI-MS, BLI, site-directed mutagenesis H25A/D29A/D48A, docking, 120 ns MD), honest dose-dependent infectivity data (OPA at 500 mM reduces infectivity >20-fold), and ESI data availability . Blind spots: affinities remain in the Β΅M range (far from nanomolar drug-like macrocycles), the 7-mer randomization constrains achievable affinity, panning/amplification bias is possible, and the authors disclose a provisional patent β a financial interest warranting independent replication. BGPT inference: the work reflects strong experimental chemistry and computational competence, but with only one paper indexed and OpenAlex metrics unavailable (rate-limited query), career-level scientific strength cannot be reliably graded.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.